Home > Financial Ratios > NATCO PHARMA

NATCO PHARMA
Core EBITDA Growth

    Back to All Ratios
NATCO PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results

NATCO PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   Core EBITDA Growth(%) 80.69186.95-48.932.87-25.41

What is the latest Core EBITDA Growth ratio of NATCO PHARMA ?

The latest Core EBITDA Growth ratio of NATCO PHARMA is 80.69 based on Mar2024 Consolidated results.
Year Core EBITDA Growth
Mar202480.69
Mar2023186.95
Mar2022-48.93
Mar20212.87
Mar2020-25.41

How is Core EBITDA Growth of NATCO PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2024 80.69
-56.84
Mar2023 186.95
Positive
Mar2022 -48.93
Negative
Mar2021 2.87
Positive
Mar2020 -25.41 -

Other Financial Ratios of NATCO PHARMA


Compare Core EBITDA Growth ratio of peers of NATCO PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
NATCO PHARMA ₹15,240.5 Cr -5.8% 3.6% -13.6% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹439,126.0 Cr 1.4% 4.1% 18.7% Stock Analytics
DIVIS LABORATORIES ₹161,568.0 Cr -2.1% 4.2% 59.1% Stock Analytics
CIPLA ₹125,156.0 Cr -0.1% 5% 9.7% Stock Analytics
TORRENT PHARMACEUTICALS ₹112,176.0 Cr -0.3% 3% 23.4% Stock Analytics
DR REDDYS LABORATORIES ₹98,716.1 Cr -1.5% 1.7% -5.4% Stock Analytics


NATCO PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
NATCO PHARMA

-5.8%

3.6%

-13.6%

SENSEX

0.2%

2.9%

8.7%


You may also like the below Video Courses